# Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

> **NCT06006117** · PHASE3 · RECRUITING · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 260 (estimated)

## Conditions studied

- Marginal Zone Lymphoma

## Interventions

- **DRUG:** Mosunetuzumab (SC)
- **DRUG:** Rituximab (R)
- **DRUG:** Bendamustine
- **DRUG:** CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT06006117
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-05
- **Primary completion:** 2027-09
- **Final completion:** 2032-09
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06006117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06006117, "Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06006117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*